Q3DM, a specialist in high-throughput microscopy (HTM) and cell-based imaging, has been awarded a grant from the US National Institutes of Health to support its development of cell-based assays for absorption, distribution, metabolism, excretion and toxicology (ADME-Tox).
ADME and toxicity analyses of compounds in preclinical screening is currently a bottleneck in drug discovery and attention is focused on ways to develop high-throughput methods that can hasten the process.
The $2.5 million award will be used to develop Q3DM's EIDAQ 100 system for HTM alongside the company's cellular analysis technologies as a high-throughput system for study ADME-Tox that can be used to weed out unsuitable compounds at the earliest stages of drug discovery
"As the price of drug discovery continues to rise, technologies are needed that can predict the toxicological properties of drug leads during preclinical testing to help avoid far more dangerous and costly failures later in the drug development cycle," said Mark McWilliams, Q3DM's chief executive.
The aim is to develop a next-generation assay technology that can interrogate cellular events in their native, three-dimensional tissue format whilst retaining the cells' functioning.